Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071372 | 0.96 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2APSMB8PSMB5PAOX | |
| SCHEMBL12896267 | 0.95 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2APSMB8PSMB5PAOX | |
| SCHEMBL469600 | 0.95 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2APSMB8PSMB5PAOX | |
| SCHEMBL10071373 | 0.95 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2APSMB8PSMB5PAOX | |
| SCHEMBL22777675 | 0.91 | SMN1; SMN2 (0.36) | SMN1; SMN2KMT2ATSHRPSMB8PSMB5 | |
| SCHEMBL34383 | 0.91 | SMN1; SMN2 (0.36) | SMN1; SMN2KMT2ATSHRPSMB8PSMB5 | |
| SCHEMBL462606 | 0.89 | ALDH1A1 (0.39) | SMN1; SMN2KMT2ATSHRPSMB8PSMB5 | |
| SCHEMBL19432859 | 0.89 | KMT2A (0.32) | SMN1; SMN2KMT2A | |
| SCHEMBL29945244 | 0.89 | SMN1; SMN2 (0.36) | SMN1; SMN2KMT2ATSHRPSMB8PSMB5 | |
| SCHEMBL19676775 | 0.88 | PAOX (0.37) | SMN1; SMN2KMT2APAOXALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121280-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-13 | — | — | WO | disclosed |
| US-20240123081-A1 | BRANCHED MOIETY FOR USE IN CONJUGATES | MEDIMMUNE, LLC | 2024-04-18 | — | — | US | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4289483-A2 | BIOMOLECULE CONJUGATES | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11739166-B2 | Reactive polysaccharide-based hemostatic agent | DAVOL INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230248759-A1 | ORAL RINSE COMPOSITIONS FOR ALLEVIATING XEROSTOMIA COMPRISING POLYETHYLENE GLYCOL DERIVATIVES | SUNBIO INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230139053-A1 | ASSAY METHOD FOR THE DETECTION OF VCAM-1 AND ALPHA-2-MACROGLOBULIN IN BLOOD | PROCISEDX INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3897736-B1 | OPTIMIZED PROCESS FOR DIMERIC PEPTIDE-PHOSPHOLIPID CONJUGATE | BRACCO SUISSE SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022178753-A1 | TARGETING CONJUGATES COMPRISING TARGETING MOIETY BINDING FRAGMENTS AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
| US-20220211900-A1 | REACTIVE DRY POWDERED HEMOSTATIC MATERIALS COMPRISING A PROTEIN AND A MULTIFUNCTIONALIZED MODIFIED POLYETHYLENE GLYCOL BASED CROSSLINKING AGENT | DAVOL INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070041901-A1 | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics | ARCHEMIX CORP. | 2007-02-22 | — | — | US | disclosed |
| US-20070041901-A1 | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics | ARCHEMIX CORP. | 2007-02-22 | — | — | US | disclosed |
| US-20030207400-A1 | Vectors for dna delivery | BIANCHI ELISABETTA (IT) | 2003-11-06 | — | — | US | disclosed |
| EP-1290198-A2 | VECTORS FOR DNA DELIVERY | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001088160-A2 | VECTORS FOR DNA DELIVERY | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI, S.P.A. (IT) | 2001-11-22 | — | — | WO | disclosed |
| US-5144010-A | Method of producing monoclonal auto-anti-idiotypic antibodies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1992-09-01 | — | — | US | disclosed |
| US-4818684-A | IMMUNOASSAY; BINDING ANTIBODY TO STEROID COMPLEX | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0236450-A1 | AUTO-ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES TO STEROID RECEPTALS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1987-09-16 | — | — | EP | disclosed |
| WO-1987001458-A1 | AUTO-ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES TO STEROID RECEPTALS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) | 1987-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070041901-A1 | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics | FOLH1, MTAP, PSMA2 | SMN1; SMN2 169/4885KMT2A 47/4885TSHR 3934/4885 |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, PLOD2, PLOD1 | SMN1; SMN2 2580/4885KMT2A 1057/4885TSHR 4792/4885 |
| US-20240123081-A1 | BRANCHED MOIETY FOR USE IN CONJUGATES | UGT2B7, UGT2B17, UGT1A1 | SMN1; SMN2 2160/4885KMT2A 2141/4885TSHR 1383/4885 |
| US-20230248759-A1 | ORAL RINSE COMPOSITIONS FOR ALLEVIATING XEROSTOMIA COMPRISING POLYETHYLENE GLYCOL DERIVATIVES | STOM, TAS2R30, TAS2R40 | SMN1; SMN2 3896/4885KMT2A 3991/4885TSHR 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.